Subscribe To

Price Alert Latest News Economic Calendar News

TOMDF / Todos Medical says Tollovir and Tollovid show robust inhibitory activity against 3CL protease of strains of Omicron variant

Todos Medical Ltd said its majority-owned subsidiary 3CL Pharma Ltd announced that its mechanism-based 3CL protease inhibitors Tollovir and Tollovidthat target the active site of the 3CL protease -- showing robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC). Additionally, the company said Tollovir and Tollovid showed inhibitory activity against the original wild-type SARS-CoV-2 strain, as well as the Alpha, Beta, Delta, and Gamma VOCs. Read More

Demo Live Account See Partner Details

Content Topics

Todos

Medical

Says

Tollovir

Tollovid

Show

Robust

Inhibitory

Activity

Against

Protease

Strains

Omicron

Variant

Stock

TOMDF

Posted: Apr 4 2022, 10:35

Author Name: Proactive Investors

TOMDF News

By Proactive Investors
March 28, 2023

Todos Medical enters LOI for Provista Diagnostics to license key PCR-based sepsis diagnostic test

Todos Medical Ltd. (OTCQB:TOMDF) announced it has entered into a letter of intent (LOI) with Acumen Diagnostics of Singapore for its CLIA/CAP-certifi

By Proactive Investors
March 15, 2023

Todos Medical expresses support for Long COVID sufferers, plans to study Tollovid's usefulness in patients

Todos Medical Ltd CEO Gerald Commissiong has shared the company's aim to open a prospective study to confirm the usefulness of its dietary supplement

By Proactive Investors
February 23, 2023

Todos Medical updates investors on its lab Provista Diagnostics, subsidiary 3CL Pharma, and Todos Botanicals automated retail rollout

Todos Medical Ltd has provided investors with an update on its corporate activities, including its moves to capitalize on the renewed interest in PCR

By GlobeNewsWire
December 6, 2022

Todos Medical to Present at the RHK 2022 Disruptive Growth Conference

New York, NY, and Tel Aviv, ISRAEL, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive

By GlobeNewsWire
November 14, 2022

Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022

NEW YORK, NY, AND TEL AVIV, ISRAEL, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical

By Proactive Investors
August 29, 2022

Todos Medical expands COVID onsite school sample collection to include MonkeyPox

Todos Medical Ltd. (OTCQB:TOMDF) has said its Atlanta-area clinical laboratory, Provista Diagnostics Inc, is expanding its onsite school sample colle

By Proactive Investors
August 26, 2022

Todos Medical says it's Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics is now offering saliva-only MonkeyPox testing

Todos Medical Ltd has announced that it's Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics Inc is now offering saliva-only M

By Proactive Investors
August 23, 2022

Todos Medical reports rise in 2Q revenue, initiates Monkeypox diagnostic case study series

Todos Medical Ltd. (OTCQB:TOMDF) has reported its financial results for the second quarter of 2022 ended June 30, 2022, showing an increase in revenue

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.